Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Pediatrics
Published in: Indian Journal of Pediatrics 9/2018

01-09-2018 | Review Article

Asthma and Medicines – Long-Term Side-Effects, Monitoring and Dose Titration

Authors: Satnam Kaur, Varinder Singh

Published in: Indian Journal of Pediatrics | Issue 9/2018

Login to get access

Abstract

Asthma is a major pediatric respiratory morbidity requiring long-term management. A thorough knowledge of long-term medication side-effects in children is, thus, essential for every physician dealing with childhood asthma. Establishing diagnosis and initiating treatment is just a beginning of the journey. Ongoing monitoring is an essential component of comprehensive asthma management programme. Monitoring includes not only assessment of asthma control but also checking for adherence to treatment, technique of inhaler device use, associated co-morbities, if any, and potential environmental exposure. Various tools – both subjective and objective - are available for assessment of asthma control. However, evidence for their optimum use in different settings and patient groups is lacking and monitoring has to be customized depending on available resources and individual patient characteristics. Patient education is an important component of long-term asthma therapy. The ultimate aim is to achieve optimum asthma control i.e., achieve and maintain control of clinical symptoms, decrease future risk to patients (risk of exacerbations, progressive loss of lung function and development of fixed airflow obstruction, adverse effects of medications) and enabling the child to lead a life without restrictions, at lowest possible dose of drugs. This article reviews the side-effects of medications used for long-term management of asthma and discusses current literature on asthma monitoring and dose titration in pediatric population to help the asthma therapist not only prescribe the drugs rationally but also help the family make right choices for treatment.
Literature
1.
Pearce N, Ait-Khaled N, Beasley R, et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2007;62:758–66.CrossRefPubMedPubMedCentral
2.
Lai CKW, Beasley R, Crane J, et al. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009;64:476–83.CrossRefPubMed
3.
Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004;126:213–9.CrossRefPubMed
4.
Dubus JC, Marguet C, Deschildre, et al. Local side effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age and device. Allergy. 2001;56:944–8.CrossRefPubMed
5.
6.
Agertoft L, Larsen FE, Pedersen S. Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide. Eur Respir J. 1998;12:130–5.CrossRefPubMed
7.
Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy. 2006;61:518–26.CrossRefPubMed
8.
Zhang L, Prietsch SO, Ducharme FM. Inhaled corticosteroids in children with persistent asthma: effects on growth. Evid Based Child Health. 2014;9:829–930.CrossRefPubMed
9.
10.
Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000;343:1064–9.CrossRefPubMed
11.
Pruteanu AI, Chauhan BF, Zhang L, Prietsch SOM, Ducharme FM. Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth. Cochrane Database Syst Rev. 2014;7:CD009878.
12.
Ferguson AC, Spier S, Manjra A, Versteegh FG, Mark S, Zhang P. Efficacy and safety of high-dose inhaled steroids in children with asthma: a comparison of fluticasone propionate with budesonide. J Pediatr. 1999;134:422–7.CrossRefPubMed
13.
Hoekx JCM, Hedlin G, Pedersen W, Sorva R, Hollingworth K, Efthimiou J. Fluticasone propionate compared with budesonide: a double-blind trial in asthmatic children using powder devices at a dosage of 400 μg/day. Eur Respir J. 1996;9:2263–72.CrossRefPubMed
14.
15.
Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med. 1999;159:941–55.CrossRefPubMed
16.
Schwartz RH, Neacsu O, Ascher DP, Alpan O. Moderate dose inhaled corticosteroid-induced symptomatic adrenal suppression: case report and review of the literature. Clin Pediatr (Phila). 2012;51:1184–90.CrossRef
17.
Smith RW, Downey K, Gordon M, et al. Prevalence of hypothalamic-pituitary-adrenal axis suppression in children treated for asthma with inhaled corticosteroid. Paediatr Child Health. 2012;17:e34–9.CrossRefPubMedPubMedCentral
18.
Zöllner EW, Lombard CJ, Galal U, Hough FS, Irusen EM, Weinberg E. Hypothalamic-pituitary-adrenal axis suppression in asthmatic school children. Pediatrics. 2012;130:e1512–9.CrossRefPubMed
19.
Issa-El-Khoury K, Kim H, Chan ES, Leek TV, Noya F. CSACI position statement: systemic effect of inhaled corticosteroids on adrenal suppression in the management of pediatric asthma. Allergy Asthma Clin Immunol. 2015;11:9.CrossRefPubMedPubMedCentral
20.
Van Staa TP, Cooper C, Leufkens HG, Bishop N. Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res. 2003;18:913–8.CrossRefPubMed
21.
Griffiths AL, Sim D, Strauss B, Rodda C, Armstrong D, Freezer N. Effect of high-dose fluticasone propionate on bone density and metabolism in children with asthma. Pediatr Pulmonol. 2004;37:116–21.CrossRefPubMed
22.
Roux C, Kolta S, Desfougères J-L, Minini P, Bidat E. Long-term safety of fluticasone propionate and nedocromil sodium on bone in children with asthma. Pediatrics. 2003;111:e706–13.CrossRefPubMed
23.
Kelly HW, Van Natta ML, Covar RA, Tonascia J, Green RP, Strunk RC, and the CAMP Research Group. Effect of long-term corticosteroid use on bone mineral density in children: a prospective longitudinal assessment in the childhood Asthma Management Program (CAMP) study. Pediatrics. 2008;122:e53–61.
24.
Tse SM, Kelly HW, Litonjua AA, Van Natta ML, Weiss ST, Tantisira KG,  and the Childhood Asthma Management Program Research Group. Corticosteroid use and bone mineral accretion in children with asthma: effect modification by vitamin D. J Allergy Clin Immunol. 2012;130:53–60.e4.
25.
Gafni RI, Baron J. Childhood bone mass acquisition and peak bone mass may not be important determinants of bone mass in late adulthood. Pediatrics. 2007;119:S131–6.CrossRefPubMed
26.
Raissy HH, Sternberg AL, Williams P, Jacobs A, Kelly HW; CAMP Research Group. Risk of cataracts in the Childhood Asthma Management Program Cohort, J Allergy Clin Immunol. 2010;126:389–92. 92.e1–4
27.
Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343:1054–63.CrossRef
28.
Lee C, Klaustermeyer WB. Effect of high dose inhaled corticosteroids on cell mediated immunity in patients with asthma. Allergol Immunopathol (Madr). 2012;40:100–3.CrossRef
29.
England RW, Nugent JS, Grathwohl KW, Hagan L, Quinn JM. High dose inhaled fluticasone and delayed hypersensitivity skin testing. Chest. 2003;123:1014–7.CrossRefPubMed
30.
Levy J, Zalkinder I, Kuperman O, et al. Effect of prolonged use of inhaled steroids on the cellular immunity of children with asthma. J Allergy Clin Immunol. 1995;95:806–12.CrossRefPubMed
31.
Yucel O, Eker Y, Nuhoglu C, Ceran O. Hemoglobin A1c levels in children with asthma using low dose inhaled corticosteroids. Indian Pediatr. 2009;46:300–3.PubMed
32.
33.
de Vries TW, De Langden-Wouterse JJ, Van Puijenbroek E, Duiverman EJ, De Jong-Van den Berg LT. Reported adverse drug reactions during the use of inhaled steroids in children with asthma in the Netherlands. Eur J Clin Pharmacol. 2006;62:343–6.CrossRefPubMed
34.
Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361:1071–6.CrossRefPubMed
35.
Capewell S, Reynolds S, Shuttleworth D, Edwards C, Finlay AY. Purpura and dermal thinning associated with high-dose inhaled corticosteroids. BMJ. 1990;300:1548–51.CrossRefPubMedPubMedCentral
36.
de Vries TW, de Langen-Wouterse JJ, de Jong-Van den Berg LT, Duiverman EJ. Hypertrichosis as a side effect of inhaled steroids in children. Pediatr Pulmonol. 2007;42:370–3.CrossRefPubMed
37.
McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D. Age and risks of FDA-approved long-acting 2-adrenergic receptor agonists. Pediatrics. 2011;128:e1147–54.CrossRefPubMed
38.
Chauhan BF, Chartrand C, Ni Chroinin M, Milan SJ, Ducharme FM. Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev. 2015;11:CD007949.
39.
Calapai G, Casciaro M, Miroddi M, Calapai F, Navarra M, Gangemi S. Montelukast-induced adverse drug reactions: a review of case reports in the literature. Pharmacology. 2014;94:60–70.CrossRefPubMed
40.
Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol. 2009;44:568–79.CrossRefPubMed
41.
Kelly KD, Spooner CH, Rowe BH. Nedocromil sodium versus sodium cromoglycate in treatment of exercise-induced bronchoconstriction: a systematic review. Eur Respir J. 2001;17:39–45.CrossRefPubMed
42.
Sridhar AV, Mckean MC. Nedochromil sodium for chronic asthma in children. Cochrane Database Syst Rev. 2006;3:CD004108.
43.
Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108:E36.CrossRefPubMed
44.
Pijnenburg MW, Baraldi E, Brand PLP, Carlsen K, Eber E, Frischer T. Monitoring asthma in children. Eur Respir J. 2015;45:906–25.CrossRefPubMed
45.
Voorend-van Bergen S, Vaessen-Verberne AA, Brackel HJ, et al. Monitoring strategies in children with asthma: a randomised controlled trial. Thorax. 2015;70:543–50.CrossRefPubMed
46.
Brand PLP. The clinician’s guide on monitoring children with asthma. Paediatr Respir Rev. 2013;14:119–25.CrossRefPubMed
47.
Lu M, Wu B, Che D, Qiao R, Gu H. FeNO and asthma treatment in children: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94:e347.CrossRef
48.
Bush A, Eber E. The value of FeNO measurement in asthma management: the motion for yes, it's NO–or, the wrong end of the stick. Paediatr Respir Rev. 2008;9:127–31.CrossRefPubMed
49.
Boulet L-P, Vervloet D, Magar Y, Foster JM. Adherence: the goal to control asthma. Clin Chest Med. 2012;33:405–17.CrossRefPubMed
50.
Trent CA, Zimbro KS, Rutledge CM. Barriers in asthma care for pediatric patients in primary care. J Pediatr Health Care. 2015;29:70–9.CrossRefPubMed
51.
Rottier BL, Eber E, Hedlin G, Turner S, Wooler E. Monitoring asthma in childhood: management-related issues. Eur Respir Rev. 2015;24:194–203.CrossRefPubMed
52.
Caponoglu M, Dibek Misirlioglu E, Toyran M, Civelak E, Kocabas CN. Evaluation of inhaler technique, adherence to therapy and their effect on disease control among children with asthma using metered dose or dry powder inhaler. J Asthma. 2015;52:838–45.CrossRef
53.
54.
Cruz AA, Popov T, Pawankar R, et al. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN. Allergy. 2007;62:1–41.CrossRefPubMed
55.
Blondeau K, Mertens V, Dupont L, et al. The relationship between gastroesophageal reflux and cough in children with chronic unexplained cough using combined impedance-pH-manometry recordings. Pediatr Pulmonol. 2011;46:286–94.CrossRefPubMed
56.
57.
Forno E, Lescher R, Strunk R, et al. Decreased response to inhaled steroids in overweight and obese asthmatic children. J Allergy Clin Immunol. 2011;127:741–9.CrossRefPubMedPubMedCentral
Metadata
Title
Asthma and Medicines – Long-Term Side-Effects, Monitoring and Dose Titration
Authors
Satnam Kaur
Varinder Singh
Publication date
01-09-2018
Publisher
Springer India
Published in
Indian Journal of Pediatrics / Issue 9/2018
Print ISSN: 0019-5456
Electronic ISSN: 0973-7693
DOI
https://doi.org/10.1007/s12098-017-2553-4

Other articles of this Issue 9/2018

Indian Journal of Pediatrics 9/2018 Go to the issue

Clinical Brief

Seasonality in Pediatric Cancer

Scientific Letter

Non-Typhoidal Salmonella Bacteremia

Scientific Letter

Chronic Inflammatory Demyelinating Polyneuropathy: A Case Series

Scientific Letter

Dihydropteridine Reductase Deficiency: A Treatable Neurotransmitter Movement Disorder Masquerading as Refractory Epilepsy Due to Novel Mutation

Editorial Commentary

Coming of Age of IAP 2015 Growth Charts: The Way Forward

Original Article

‘Quality of Life’ of Parents of Children Suffering from Pediatric Malignancies in a Low Income Setting